Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal

Potential In Cardiovascular Indications

 
• By Jung Won Shin
  
Biggest Deal
Korea's Chong Kun Dang strikes its biggest ever licensing deal • Source: Shutterstock

More from Business

More from Scrip